Allworth Financial’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Allworth Financial’s Portfolio BBC Stock Details BBC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$527	Hold	10	–	–	﹤0.01%	4844
2026 Q1	$417	Hold	10	–	–	﹤0.01%	4778
2025 Q4	$386	Hold	10	–	–	﹤0.01%	4585
2025 Q3	$273	Hold	10	–	–	﹤0.01%	4560
2025 Q2	$194	Hold	10	–	–	﹤0.01%	4319
2025 Q1	$187	Hold	10	–	–	﹤0.01%	3883
2024 Q4	$229	Hold	10	–	–	﹤0.01%	3760
2024 Q3	$280	Hold	10	–	–	﹤0.01%	3534
2024 Q2	$278	Hold	10	–	–	﹤0.01%	3504
2024 Q1	$292	Hold	10	–	–	﹤0.01%	3401
2023 Q4	$245	Hold	10	–	–	﹤0.01%	3263
2023 Q3	$197	Hold	10	–	–	﹤0.01%	3236
2023 Q2	$240	Hold	10	–	–	﹤0.01%	3061
2023 Q1	$220	Hold	10	–	–	﹤0.01%	2993
2022 Q4	$250	Buy	+10	New	+$249	﹤0.01%	2752

Other funds holding BBC

Kera Capital Partners San Jose, California $1.04B AUM 52.56% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Militia Capital Management Austin, Texas $3.37B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Allworth Financial's BBC Position: Q2 2026 in Review

Allworth Financial held its Virtus Biotech Clinical Trials ETF (BBC) position steady in Q2 2026 at 10 shares worth $527. The position accounts for ﹤0.01% of the portfolio, ranked #4844.

Allworth Financial first reported a position in BBC in Q4 2022 and has held it in 15 quarters since. 20 funds tracked by Wall St. Rank hold BBC as of Q2 2026.

Allworth Financial held 10 shares of Virtus Biotech Clinical Trials ETF worth $527 as of Q2 2026.
Allworth Financial left its Virtus Biotech Clinical Trials ETF share count unchanged in Q2 2026.
Virtus Biotech Clinical Trials ETF made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #4844 holding.
Allworth Financial first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2022 and has held it in 15 quarters since.
20 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.